ASND
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock trades at a premium to book value and lacks traditional valuation anchors, but forward P/E is relatively attractive given growth expectations
- Forward P/E of 17.77 is below sector average (164.56)
- Price/Sales of 19.27 is elevated but justified by growth profile
- No Graham Number or intrinsic value formula available
- Negative ROE and profit margin undermine traditional valuation models
Growth metrics are among the strongest in the sector, though profitability remains a concern
- 42.3% YoY revenue growth is exceptional
- High growth trajectory aligns with biotech sector leadership
- No earnings growth data available
- Sustainability of growth depends on R&D success and commercialization
Historical performance is strong, but financial health metrics show deterioration
- 5-year stock return of +53.7% and 3-year return of +106.6%
- Consistent outperformance vs. sector peers
- Negative ROA (-6.86%) and declining profitability trends
- Lack of consistent cash flow generation
Financial health is weak; the low Piotroski score reflects poor profitability, negative ROA, and lack of cash flow
- Current ratio of 1.04 suggests short-term liquidity is adequate
- Quick ratio of 0.72 indicates some liquidity pressure but not critical
- Piotroski F-Score of 2/9 is extremely low, signaling financial distress
- No Altman Z-Score available, but low F-Score implies distress risk
Company is reinvesting all capital into growth; no dividend income potential
- No dividend yield or payout ratio
- Dividend strength is 0/100, indicating no dividend policy
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ASND and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ASND
Ascendis Pharma A/S
Primary
|
+53.7% | +106.6% | +48.4% | +15.5% | +2.0% | -6.1% |
|
RGC
Regencell Bioscience Holdings Limited
Peer
|
+10275.8% | +3861.7% | +3641.3% | +64.7% | +8.7% | -0.5% |
|
PODD
Insulet Corporation
Peer
|
-28.4% | -37.3% | -19.6% | -36.3% | -12.6% | +1.0% |
|
NBIX
Neurocrine Biosciences, Inc.
Peer
|
+34.2% | +30.1% | +19.1% | -6.2% | -0.5% | +3.0% |
|
MEDP
Medpace Holdings, Inc.
Peer
|
+174.6% | +172.4% | +78.2% | -5.6% | +12.7% | -1.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ASND
Ascendis Pharma A/S
|
BULLISH | $13.87B | - | -% | -31.7% | $225.98 | |
|
RGC
Regencell Bioscience...
|
BEARISH | $14.18B | - | -54.8% | -% | $28.67 | Compare |
|
PODD
Insulet Corporation
|
NEUTRAL | $14.18B | 57.73 | 18.1% | 9.1% | $201.47 | Compare |
|
NBIX
Neurocrine Biosciences, Inc.
|
BULLISH | $13.22B | 28.15 | 16.4% | 16.7% | $131.74 | Compare |
|
MEDP
Medpace Holdings, Inc.
|
NEUTRAL | $14.7B | 34.6 | 70.2% | 17.8% | $514.9 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning ASND from our newsroom.